Deccan Health Care
12.20
+0.43(+3.65%)
Market Cap₹30.16 Cr
PE Ratio12.79
Company Performance:
1D+3.65%
1M+66.67%
6M-24.55%
1Y-30.92%
5Y-64.01%
View Company Insightsright
More news about Deccan Health Care
14Nov 25
Deccan Health Care Reports Robust Q2 Growth: Revenue Surges 29.7%, Profit Jumps 67.5%
Deccan Health Care reported robust Q2 FY2025-26 results with revenue increasing 29.7% YoY to ₹2,440.46 lakh and net profit surging 67.5% to ₹89.97 lakh. EBITDA margin improved to 7.0% from 3.4%. The company expanded its wellness portfolio with new product launches and introduced a Weight Wellness Program. Deccan Health Care is pursuing international growth with regulatory approvals filed in 6 markets and plans for product launches in UAE and GCC by March 2026.
 no imag found
01Oct 25
Deccan Health Care Reappoints Ruchi Khattar as Independent Director for Second Term
Deccan Health Care Limited has reappointed Ruchi Khattar as an Independent Director in the Non-Executive category for a second term of five years, from September 4, 2025, to September 3, 2030. The decision was approved by shareholders at the company's 29th Annual General Meeting. Khattar, with 25 years of experience in accounts, finance, and insurance compliance, is a graduate from Lady Sri Ram College, Delhi University. The company confirmed that Khattar is not related to any other directors and is not debarred from holding a directorship by any regulatory authority.
 no imag found
04Sept 25
Deccan Health Care Reappoints Ruchi Khattar as Independent Director, Approves Annual Report
Deccan Health Care's board has reappointed Ruchi Khattar as Independent Director for a second five-year term, approved the annual report for FY 2024-25, and scheduled the 29th AGM for September 30, 2025. The board also appointed M/s. M. R. Bhatia and Co. as Secretarial Auditors for five years and made decisions regarding the e-voting process and disclosure of material events.
 no imag found
14Aug 25
Deccan Health Care Limited Approves Q1 FY2026 Financial Results
Deccan Health Care Limited's Board of Directors approved the unaudited financial results for Q1 FY2026 ending June 30, 2025. The board meeting was held on August 14, 2025, via video conferencing. Both standalone and consolidated results were approved after review by the Audit Committee. Director Mohak Gupta is authorized to sign the results. The company will upload the results on its website and submit them to BSE Limited, complying with SEBI regulations.
 no imag found
Deccan Health Care
12.20
+0.43
(+3.65%)
1 Year Returns:-30.92%
Industry Peers
Dr. Lal Path Labs
1,397.80
(-0.98%)
Vijaya Diagnostic Centre
1,114.05
(+0.33%)
Metropolis Healthcare
478.80
(-0.43%)
Krsnaa Diagnostics
580.95
(-1.50%)
Suraksha Diagnostic
280.77
(-0.88%)
3B BlackBio DX
1,264.70
(-3.50%)
Sastasundar Ventures
282.60
(+3.86%)